Health Care·Health Care Equipment·$125.4B
Stryker Corp (SYK) is a leading medical technology company that develops and manufactures innovative healthcare equipment and devices. Operating in the Health Care sector, Stryker focuses on products that enhance surgical procedures and improve patient outcomes, making it a key player in the growing healthcare equipment industry.
EPS
Earnings per share (EPS) is a critical measure of profitability and helps investors gauge the company's financial health.
Revenue
Total revenue indicates the company's overall sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+2.93%
Avg Stock Reaction
-0.63%
In Q4-2025, Stryker reported an EPS of $4.47, beating estimates by 1.71%. However, the stock experienced a slight decline the following day.
Management Promises & Guidance
Analysts expect Stryker to report strong earnings driven by robust demand for its healthcare products. However, there are concerns about potential market pressures.
Bull Case
If Stryker exceeds EPS and revenue estimates, it could signal strong operational performance and market confidence, leading to stock appreciation.
Bear Case
If the company fails to meet expectations or provides weak guidance, it may raise concerns about future growth and impact the stock negatively.
EPS
$2.98Earnings per share (EPS) is a critical measure of profitability and helps investors gauge the company's financial health.
Revenue
$6.3BTotal revenue indicates the company's overall sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will Stryker achieve an EPS of $2.98 or better?
This is crucial for confirming the company's profitability and growth trajectory, which investors will closely monitor.
Q2
What is the outlook for revenue growth compared to the consensus of $6.3B?
Revenue performance will indicate market demand and the effectiveness of Stryker's product offerings.
Why consensus could be wrong
The consensus may underestimate Stryker's ability to innovate and capture market share, particularly in emerging healthcare technologies.
Supporting Evidence
Stryker's historical EPS beat rate of 100% suggests strong operational execution.
Options pricing indicates high volatility, which may not reflect the company's stable growth trajectory.
Recent product launches have shown promising early adoption rates that could drive future revenue.
Key Risk
If Stryker's revenue growth exceeds $6.5B, it could challenge the current market narrative of slowing demand.
Pre-commit to what would confirm each case.
The market is debating whether Stryker can sustain its growth momentum amid increasing competition and market pressures.
Bull Confirmed If
Achieving an EPS of $3.07 or higher would confirm strong operational performance and investor confidence.
Bear Confirmed If
An EPS below $2.86 would raise concerns about Stryker's growth prospects and market position.
Implied Move
±5.32%
Historical Avg
±0.8%
The options market is pricing in a significant move around the earnings announcement, indicating heightened investor uncertainty.
Options are pricing ±5.3% while SYK has averaged ±0.8% over the last 8 prints — setup is pricing rich.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Stryker beats expectations, history suggests a modest stock increase, confirming strong operational health.
In-Line / Cautious
An inline report may lead to cautious trading as investors await further guidance from management.
Miss
If Stryker misses estimates, the stock could see a decline, reflecting investor disappointment based on past reactions.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERIZON COMMUNICATIO
Apr 27, 2026